Living Health Technology Assessment: Issues, Challenges and Opportunities
AbstractHealth technology assessments (HTAs) are typically performed as one-off evaluations and can potentially become out-of-date due to the availability of new data, new comparators, or other factors. Recently, living approaches have been applied to systematic reviews and network meta-analyses to enable evidence syntheses to be updated more easily. In this paper, we provide a definition for ‘Living HTA’ where such a living approach could be applied to the entire HTA process. Living HTA could involve performing regular or scheduled updates using a traditional manual approach, or indeed in a semi-automated manner lever...
Source: PharmacoEconomics - February 27, 2023 Category: Health Management Source Type: research
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?
Conclusions on cost effectiveness were altered in 2/16 scenarios across the four case examples.ConclusionsGiven the decision context that US payers face, with prices varying over time, findings suggest further research to reduce uncertainty around price trajectories, as well as conducting or updating multiple assessments over the lifecycle of pharmaceutical products. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 27, 2023 Category: Health Management Source Type: research
Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment
ConclusionsThe current use of disutilities of AEs in CUAs shows some discrepancies with recommendations proposed in the literature. One is that detailed information about the use of disutilities of AEs was not reported and the other is that essential methods to analyze the impact of AEs on quality-adjusted life-years were not thoroughly conducted. Therefore, it is suggested that researchers should attach importance to the impact of AEs on health-related quality of life. Furthermore, an application process was developed for the disutilities of AEs to remind and guide researchers to correctly use the disutilities of AEs as p...
Source: PharmacoEconomics - February 27, 2023 Category: Health Management Source Type: research
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
AbstractThe National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgotinib (Jyseleca®), as part of the Single Technology Appraisal process, to submit evidence for the clinical effectiveness and cost effectiveness of filgotinib for treating moderately to severely active ulcerative colitis in adults who have had an inadequate response, loss of response or were intolerant to a previous biologic agent or conventional therapy. Kleijnen Systematic Reviews Ltd, in collaboration with Maastricht University Medical Centre+, was commissioned to act as the independent Evidence Review Group. This ...
Source: PharmacoEconomics - February 27, 2023 Category: Health Management Source Type: research
Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review
ConclusionsDespite the relatively high prevalence of OCD worldwide, cost-effectiveness data for therapeutic modalities remain sparse. Because of the chronic nature of OCD, the cost of treatment accumulates and may lead to a significant financial burden over time, particularly when non-evidence-based interventions are used. However, several alternative therapeutic modalities hold promise for economic practicality without significant sacrifice in clinical efficacy. Future studies are necessary to directly compare the cost effectiveness of such therapeutic alternatives with the current standard of care, CBT with exposure and ...
Source: PharmacoEconomics - February 25, 2023 Category: Health Management Source Type: research
How to Predict Drug Expenditure: A Markov Model Approach with Risk Classes
ConclusionThe long-term development of pharmaceutical spending in Germany will depend mainly on future expenditure and life expectancy trends of particularly high-cost patients. Thus, appropriate pricing of new expensive pharmaceuticals is essential for the sustainability of the German healthcare system. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 25, 2023 Category: Health Management Source Type: research
Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review
ConclusionsDespite the relatively high prevalence of OCD worldwide, cost-effectiveness data for therapeutic modalities remain sparse. Because of the chronic nature of OCD, the cost of treatment accumulates and may lead to a significant financial burden over time, particularly when non-evidence-based interventions are used. However, several alternative therapeutic modalities hold promise for economic practicality without significant sacrifice in clinical efficacy. Future studies are necessary to directly compare the cost effectiveness of such therapeutic alternatives with the current standard of care, CBT with exposure and ...
Source: PharmacoEconomics - February 25, 2023 Category: Health Management Source Type: research
HTA Barriers for Conditional Approval Drugs
ConclusionsOverall, conditionally approved drugs likely face increased barriers at the HTA level. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 23, 2023 Category: Health Management Source Type: research
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK
ConclusionsThese individual-level healthcare cost prediction models could inform assessments of the value of health technologies and policies to reduce cardiovascular and other disease risks and healthcare costs. An accompanying Excel calculator is available to facilitate the use of the models. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 23, 2023 Category: Health Management Source Type: research
HTA Barriers for Conditional Approval Drugs
ConclusionsOverall, conditionally approved drugs likely face increased barriers at the HTA level. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 23, 2023 Category: Health Management Source Type: research
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
DiscussionAlthough (mild) AEFI were demonstrated for all five studied vaccines, only a quarter of reviewed studies accounted for these, mostly in an incomplete and inaccurate manner. We provide guidance on which methods to use to better quantify the impact of AEFI on both costs and health outcomes. Policymakers should be aware that the impact of AEFI on cost-effectiveness is likely to be underestimated in the majority of economic evaluations. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 21, 2023 Category: Health Management Source Type: research
